<DOC>
	<DOCNO>NCT01841996</DOCNO>
	<brief_summary>This study Randomized , Double-Blind , Vehicle-Controlled , Multiple-Dose Study . The purpose determine safety , tolerability , systemic exposure pharmacokinetics ME1111 repeat daily topical application ME1111 maximal use set adult distal subungual onychomycosis toenail .</brief_summary>
	<brief_title>Pharmacokinetics Safety Study ME1111 Moderate Severe Onychomycosis Patients</brief_title>
	<detailed_description />
	<mesh_term>Onychomycosis</mesh_term>
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<criteria>1 . Male female race age 18 70 inclusive 2 . Clinically diagnosed onychomycosis target nail 3 . Presence moderate severe distal subungual onychomycosis 4 . A positive potassium hydroxide ( KOH ) microscopy test result 5 . A positive fungal culture dermatophyte 6 . Females childbearing potential must use highly effective method birth control willing remain method birth control throughout study 7 . Good general health determine Investigator base subject 's medical history physical examination 1 . Clinical significant laboratory abnormality would interfere conduct interpretation study jeopardize subject 's safety 2 . Subjects history diabetes mellitus 3 . Unwilling refrain use nail cosmetic clear and/or color nail solution 4 . Females nurse , pregnant , plan pregnancy study 5 . Failure complete specify washout period ( ) follow topical medication : Antifungals drug within 4 week ; Antiinflammatory drug , corticosteroid , immunomodulators within 2 week 6 . Failure complete specify washout period ( ) follow systemic medication : Corticosteroids within 2 week ; Antifungals treatment onychomycosis antifungal know activity dermatophyte within previous 24 week 5 halflives drug , whichever longer ; Immunomodulators within 4 week 7 . History cardiac disease cardiac arrhythmic activity , prolong QT interval 8 . Received treatment type cancer within last 6 month 9 . History significant disease disorder might put subject risk participate study influence result study 10 . Nail anatomic abnormality toe 11 . Positive test HIV , Hepatitis B Hepatitis C 12 . History street drug alcohol abuse 13 . Donated lose blood participate clinical study involve withdrawal large volume blood ( 500 mL ) , within last 6week 14 . Participated trial investigational drug device within 30 day 5 halflives investigational drug participation research study concurrent study 15 . Unable communicate cooperate Investigator due comprehension , mental development , impaired cerebral function 16 . Presence underlying disease Investigator deem uncontrolled , pose concern subject safety participate study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>December 2013</verification_date>
</DOC>